Research sheds light on how steroids affect cancer Immunotherapy

Immunotherapy is among the newest and most potent weapons against cancer. It prompts the immune system to recognize tumors as intruders in the body and attack. But not all patients respond well to immunotherapy. Why? Scientists aren't always sure.

Sometimes, immunotherapy patients experience side effects that steroids called glucocorticoids (GCs) can treat. GCs are often used to regulate the immune response in conditions such as asthma, Crohn's disease, and even COVID-19. Yet just how they work is also a mystery.

Now, Cold Spring Harbor Laboratory (CSHL) researchers may be closer to answering both questions. Their new research indicates GCs may indirectly lead to some immunotherapy treatment failures by driving the production of a protein called Cystatin C (CyC). Higher levels of CyC are linked to poorer outcomes of this type of therapy.

GCs are very powerful suppressors of immunity and are consequently used to treat autoimmunity," which is when the immune system attacks healthy cells. "We've previously shown that GCs can also break cancer immunotherapy. Now, here's perhaps a clue into how they're doing it."

Tobias Janowitz, Assistant Professor, CSHL

Janowitz's lab studies the whole-body response to cancer. For this study, he and a Ph.D. student in his lab, physician-turned-researcher Sam Kleeman, teamed with a third CSHL scientist, Assistant Professor Hannah Meyer, an expert in quantitative biology. Together, they analyzed a massive genetic dataset from the UK Biobank. How massive? Almost 500,000 volunteers, including patients with cancer. Kleeman also reached out to researchers overseas to gather even more patient data.

The scientists found that patients who were more likely to produce CyC in response to GCs had a worse overall survival rate. These patients were also less likely to benefit from treatment. This suggests CyC production within a tumor may contribute to the failure of cancer immunotherapy.

To confirm CyC's connection with cancer, the researchers turned to good old-fashioned lab work. In mice, they deleted a CyC-producing gene so it was no longer present in cancer cells. They found that tumors without CyC grew slower.

"It's really powerful to come at this from multiple angles and support the findings through many approaches," Meyer says. "Clever genetic models gave us some indication of which experiments to design to help us answer the question of what this molecule does."

Janowitz says he plans to continue studying CyC. He hopes this could greatly help future patients.

"The research has given me an impetus to find out more about the function of this molecule, specifically in the context of cancer immunotherapy," he says. "Perhaps its function can be targeted to enhance the success of cancer immunotherapy."

Journal reference:

Kleeman, S., et al. (2023) Cystatin C is glucocorticoid-responsive, directs recruitment of Trem2+ macrophages and predicts failure of cancer immunotherapy. Cell Genomics.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Blood cancer drug could help improve the efficiency of radiotherapy in meningiomas